Portage Biotech Inc. (PRTG)

Market Cap	6.68M
Revenue (ttm)	n/a
Net Income (ttm)	-67.28M
Shares Out	1.12M
EPS (ttm)	-63.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,127
Open	5.40
Previous Close	5.85
Day's Range	5.40 - 6.34
52-Week Range	2.10 - 40.80
Beta	1.53
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 26, 2024

About PRTG

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1973
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTG
• Website: https://www.portagebiotech.com